Tech & AI
OpenAI buys Orchestra Bio to push its AI agents into drug development
The deal, whose terms were not disclosed, extends OpenAI's life-sciences push as rival Anthropic builds its own biology business.
HedgeWeekly Tech & AI Desk ·
OpenAI has acquired Orchestra Bio, a start-up whose software helps pharmaceutical companies run drug development programmes, the companies said on Tuesday after Axios first reported the deal. Financial terms were not disclosed.
Orchestra's platform lets AI agents, software that carries out multi-step tasks on its own, take over routine work such as monitoring studies, tracking timelines and flagging likely delays. Scientists and programme leaders then decide what to do next. In one example, if a failed manufacturing batch threatens a clinical trial, the agents identify the affected work, gather the relevant data and set out possible responses.
OpenAI plans to fold Orchestra's team and technology into Rosalind, its suite of models and tools for life-sciences researchers, which it introduced in April. OpenAI already works with Novo Nordisk and Moderna on bringing AI into research and development. Anthropic, its main rival, bought AI biotech start-up Coefficient Bio in April for roughly $400 million, according to The Information, and launched a science research platform in June.
Why it matters: Most AI spending in pharma has gone to early drug discovery, while the day-to-day running of trials, where delays are costly, is still largely manual. With OpenAI and Anthropic both expected to court public investors, moves into large industries such as pharma help support their revenue stories. Investors should watch for paying pharma customers, any measurable cut in development timelines, and the effect on listed providers of clinical-trial software and services.